Skip to main content
Caplight Logo









Eyerising International

Eyerising International

Private
South YarraHealthcare & Life Scienceshttps://eyerisinginternational.com/

Last Round

Accelerator

May 19, 2026

Total Funding Raised

$10,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Eyerising International is a medical technology company that develops and markets the Eyerising Myopia Management Device, a home-use medical device utilizing repeated low-level red-light (RLRL) therapy to slow the progression of myopia in children.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Patient Engagement, Healthcare Analytics

Business Model

B2B2C

Customer Profile

Hardware + Subscription, Hardware Sales

AI Layer

Application

Keywords

myopia managementRLRL therapyrepeated low-level red-lightpediatric eye caremyopia controlmedical devicepatient compliance monitoringophthalmology technologyB2B2Cremote patient monitoringRPMhealthcare softwaredigital healthmedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eyerising International Comparables

Compare Eyerising International with similar companies based on industry and business-model similarity.

Eyerising International comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Beijing Yishiliang Medical Technology Co., Ltd.
88%
Dopavision
82%
Beijing Mingren Shikang Science & Technology Co., Ltd.
80%

Eyerising International Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorMay 19, 2026
Series AFeb 16, 2026
GrantNov 7, 2025

Eyerising International Investors

Notable investors and investment history

Eyerising International investors
InvestorRounds
MedTech InnovatorAccelerator
Hong Kong Science and Technology Parks CorporationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 19, 2026

    Received funding from MedTech Innovator.

  • Apr 22, 2026

    Grew 43% QoQ, from 7 to 10 employees.

Eyerising International Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Eyerising International Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Eyerising International's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth Yarra
Employee Range9
Year Founded2020
Last FundingMay 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?